Conversion TORS after neoadjuvant immunotherapy for advanced BOT-SCC: a retrospective study
Neoadjuvant therapy may render a subset of patients with advanced BOT-SCC eligible for TORS, enabling oncologically radical resection with low perioperative morbidity and promising early functional recovery. Prospective studies are warranted to validate patient selection criteria and to develop biomarker-guided de-intensification strategies.
Authors
- Quanquan Lin (ORCID: https://orcid.org/0000-0001-7330-3051)
- Yipeng Ren
- F. Wang
- H L Zhang
- Qing Xi
- Boning Cai
- Jinlong Sun
- Lin Feng
- Yingjuan Zhang
- Xiuli Hui
- Zhiyong Wu
- Zhigang Song
Institutions
- Chinese PLA General Hospital (CN)
- People's Liberation Army No. 150 Hospital (CN)
- The 309th Hospital of Chinese People's Liberation Army (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fonc.2025.1709974
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00